1 |
Ramos, P. and Bentires-Alj, M. (2015) Mechanism-based cancer therapy: resistanceto therapy, therapy for resistance. Oncogene, 34, 3617-3626.
DOI
|
2 |
Gorrini, C., Harris, I.S. and Mak, T.W. (2013) Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov., 12, 931-947.
DOI
|
3 |
Trachootham, D., Alexandre, J. and Huang, P. (2009) Target-ing cancercells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 8, 579-591.
DOI
|
4 |
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E.C., Zhang, H., Huang, C. and Lei, Y. (2016) Cancer drug resistance: redox resetting renders a way. Oncotarget, 7, 42740-42761.
DOI
|
5 |
Debatin, K.M. and Krammer, P.H. (2004) Death receptors in chemotherapy and cancer. Oncogene, 23, 2950-2966.
DOI
|
6 |
Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A. and Zhang, D.D. (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U.S.A., 108, 1433-1438.
DOI
|
7 |
DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., Scrimieri, F., Winter, J.M., Hruban, R.H., Iacobuzio- Donahue, C., Kern, S.E., Blair, I.A. and Tuveson, D.A. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475, 106-109.
DOI
|
8 |
Zhang, Y. and Gordon, G.B. (2004) A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway. Mol. Cancer Ther., 3, 885-893.
|
9 |
Chio, I.I., Jafarnejad, S.M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Ohlund, D., Wright, K., Filippini, D., Lee, E.J., Da Silva, B., Schoepfer, C., Wilkinson, J.E., Buscaglia, J.M., DeNicola, G.M., Tiriac, H., Hammell, M., Crawford, H.C., Schmidt, E.E., Thompson, C.B., Pappin, D.J., Sonenberg, N. and Tuveson, D.A. (2016) NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell, 166, 963-976.
DOI
|
10 |
Giudice, A., Arra, C. and Turco, M.C. (2010) Review of molecular mechanisms involved in the activation of the Nrf2- ARE signaling pathway by chemopreventive agents. Methods Mol. Biol., 647, 37-74.
|
11 |
Sporn, M.B. and Liby, K.T. (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer, 12, 564-571.
DOI
|
12 |
Na, H.K. and Surh, Y.J. (2014) Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic. Biol. Med., 67, 353-365.
DOI
|
13 |
Shen, L., Song, C.X., He, C. and Zhang, Y. (2014) Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu. Rev. Biochem., 83, 585-614.
DOI
|
14 |
Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C. and Zhang, Y. (2011) Tet proteins can convert 5- methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science, 333, 1300-1303.
DOI
|
15 |
Shilatifard, A. (2008) Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr. Opin. Cell Biol., 20, 341-348.
DOI
|
16 |
Coward, W.R., Feghali-Bostwick, C.A., Jenkins, G., Knox, A.J. and Pang, L. (2014) A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. FASEB J., 28, 3183-3196.
DOI
|
17 |
Li, Z., Xu, L., Tang, N., Xu, Y., Ye, X., Shen, S., Niu, X., Lu, S. and Chen, Z. (2014) The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. FEBS Lett., 588, 3000-3007.
DOI
|
18 |
Yang, D., Okamura, H., Teramachi, J. and Haneji, T. (2016) Histone demethylase Jmjd3 regulates osteoblast apoptosis through targeting anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bim. Biochim. Biophys. Acta, 1863, 650-659.
DOI
|
19 |
Wang, R., An, J., Ji, F., Jiao, H., Sun, H. and Zhou, D. (2008) Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun., 373, 151-154.
DOI
|
20 |
Muscarella, L.A., Barbano, R., D’Angelo, V., Copetti, M., Coco, M., Balsamo, T., la Torre, A., Notarangelo, A., Troiano, M., Parisi, S., Icolaro, N., Catapano, D., Valori, V. M., Pellegrini, F., Merla, G., Carella, M., Fazio, V.M. and Parrella, P. (2011) Regulation of Keap1 expression by promoter methylation in malignant gliomas and association with patient’s outcome. Epigenetics, 6, 317-325.
DOI
|
21 |
Kang, K.A., Piao, M.J., Kim, K.C., Kang, H.K., Chang, W.Y., Park, I.C., Keum, Y.S., Surh, Y.J. and Hyun, J.W. (2014) Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis., 5, e1183.
DOI
|
22 |
Kang, K.A., Piao, M.J., Ryu, Y.S., Kang, H.K., Chang, W.Y., Keum, Y.S. and Hyun, J.W. (2016) Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells. Oncotarget, 7, 40594-40620.
DOI
|
23 |
Mohan, M., Herz, H.M., Smith, E.R., Zhang, Y., Jackson, J., Washburn, M.P., Florens, L., Eissenberg, J.C. and Shilatifard, A. (2011) The COMPASS family of H3K4 methylases in Drosophila. Mol. Cell. Biol., 31, 4310-4318.
DOI
|
24 |
Yokoyama, A., Wang, Z., Wysocka, J., Sanyal, M., Aufiero, D.J., Kitabayashi, I., Herr, W. and Cleary, M.L. (2004) Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol., 24, 5639-5649.
DOI
|
25 |
Deplus, R., Delatte, B., Schwinn, M.K., Defrance, M., Méndez, J., Murphy, N., Dawson, M.A., Volkmar, M., Putmans, P., Calonne, E., Shih, A.H., Levine, R.L., Bernard, O., Mercher, T., Solary, E., Urh, M., Daniels, D.L. and Fuks, F. (2013) TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J., 32, 645-655.
DOI
|
26 |
Ardehali, M.B., Mei, A., Zobeck, K.L., Caron, M., Lis, J.T. and Kusch, T. (2011) Drosophila Set1 is the major histone H3 lysine 4 trimethyltransferase with role in transcription. EMBO J., 30, 2817-2828.
DOI
|
27 |
Capotosti, F., Guernier, S., Lammers, F., Waridel, P., Cai, Y., Jin, J., Conaway, J.W., Conaway, R.C. and Herr, W. (2011) OGlcNAc transferase catalyzes site-specific proteolysis of HCF-1. Cell, 144, 376-388.
DOI
|
28 |
Ding, X., Jiang, W., Zhou, P., Liu, L., Wan, X., Yuan, X., Wang, X., Chen, M., Chen, J., Yang, J., Kong, C., Li, B., Peng, C., Wong, C.C., Hou, F. and Zhang, Y. (2015) Mixed lineage leukemia 5 (MLL5) protein stability is cooperatively regulated by O-GlcNac transferase (OGT) and ubiquitin specific protease 7 (USP7). PLoS ONE, 10, e0145023.
DOI
|
29 |
Furfaro, A.L., Piras, S., Domenicotti, C., Fenoglio, D., De Luigi, A., Salmona, M., Moretta, L., Marinari, U.M., Pronzato, M.A., Traverso, N. and Nitti, M. (2016) Role of Nrf2, HO-1 and GSH in neuroblastoma cell resistance to bortezomib. PLoS ONE, 11, e0152465.
DOI
|
30 |
Bai, X., Chen, Y., Hou, X., Huang, M. and Jin, J. (2016) Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab. Rev., 48, 541-567.
DOI
|
31 |
Holohan, C., Van Schaeybroeck, S., Longley, D.B. and Johnston, P.G. (2013) Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer, 13, 714-726.
DOI
|
32 |
Guo, Y., Yu, S., Zhang, C. and Kong, A.N. (2015) Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic. Biol. Med., 88, 337-349.
DOI
|
33 |
Seton-Rogers, S. (2016) Chemotherapy: preventing competitive release. Nat. Rev. Cancer, 16, 199.
|